We have a strong preclinical pipeline fully owned and IP-protected. Our engineered bacteria deliver diverse cargos larger than other vehicles can handle, and are equipped with safety switches and other smart controls.
Lead asset RONC1 against pancreatic cancer
Collaboration with large-cap pharma in progress
Target the right cells in the right tissues
Enhance efficacy where needed
We welcome additional industry partnerships. Please contact us for further details.